GLP-1s and Fatty Liver: What the Phase 3 Trial Showed

Fatty liver disease is the condition most likely to be sitting underneath a GLP-1 prescription without anyone having mentioned it. In 2025 a phase 3 trial reported that semaglutide resolved steatohepatitis without worsening fibrosis in 62.9% of patients.^[1] That figure has been quoted everywhere. The one quoted far less often is the placebo arm: 34.3%.

What the trial found

ESSENCE randomized 1,197 patients with biopsy-confirmed MASH and fibrosis at stage 2 or 3, two to one, to weekly semaglutide 2.4 mg or placebo. It is designed to run 240 weeks. What has been published is a planned interim analysis at week 72, covering the first 800 patients.^[1]

The wider evidence agrees

A 2025 meta-analysis in Liver International pooled 13 phase 2 and phase 3 randomized trials covering 1,811 participants. Among people with MASH and moderate-to-advanced fibrosis, GLP-1 drugs — semaglutide 2.4 mg especially — beat placebo for resolution, with a pooled odds ratio of 3.48, and for fibrosis improvement, at 1.79. Both with no measurable heterogeneity between trials.^[2]

Liver fat measured by MRI fell by a pooled 4.50 percentage points across nine trials, although that estimate varied enormously between studies.^[2] Consistency across independent trials is the strongest form this kind of evidence takes, and on the resolution and fibrosis endpoints it is there.

Where it stops working

This is the part that matters most to the people with the most at stake, and it is almost never in the coverage. In the same meta-analysis, among people whose MASH had already progressed to compensated cirrhosis, semaglutide produced neither resolution nor fibrosis improvement compared with placebo.^[2]

The benefit is in the stages before cirrhosis. Once cirrhosis is established, the single trial available found nothing.

That rests on one randomized trial, so it is a signal rather than a settled answer, and it may change. But it points the same way as most of hepatology: fibrosis becomes progressively harder to reverse the further it has gone, and the argument for acting early is an argument about the window, not about the drug.

What this does and does not change for a reader

• If you are on a GLP-1 for weight, this is a plausible bonus and not a treatment plan. MASH is diagnosed by biopsy or by imaging, and nobody can tell you what your liver is doing from your weight.
• The trial population was specific — biopsy-confirmed MASH at fibrosis stage 2 or 3. Results in that group do not automatically describe simple fatty liver without inflammation, which is a different and much more common situation.
• Weight loss and liver improvement traveled together here, with a mean loss of 10.5% against 2.0%.^[1] Untangling how much of the liver benefit is the drug and how much is the weight is not something this trial settles.
• It is an interim result. ESSENCE runs to 240 weeks; what has reported is week 72 in the first 800 of 1,197 patients.^[1] The durable-outcomes question is genuinely still open.

If liver disease is part of why a GLP-1 was suggested to you, that is a conversation for the clinician holding your imaging and bloodwork. Our evidence-duration piece covers how far the randomized record extends, and the trial tracker follows what is still running, including newer drugs such as survodutide, which pairs GLP-1 with glucagon and is in phase 3 for MASH.